With the company providing so much information, there are a lot of possible interpretations of whether Sanofi-Aventis
Sales for the second quarter rose 6.5% on a reported basis and 10.1% on a "comparable" basis that adjusts for the Aventis merger and foreign currency effects. Margins were quite solid once again: Gross margin improved to nearly 79%, and operating margin climbed to 33.7%. Adjusted net income rose by 26%.
The company's top drugs led the way again, with the top 15 compounds bringing revenue growth of 16.2% in the quarter and making up more than 60% of the company's total. Market-leading drugs like Lovenox, Plavix, and Lantus were all quite strong and posted double-digit growth. The vaccine business also had a good quarter, as a new meningitis/pneumonia vaccine helped push sales up more than 13%.
Sanofi-Aventis generated more than $3.5 billion in free cash flow (before dividends) and has managed to repay close to $2 billion in debt so far this year. Based on the strong results, management raised earnings growth guidance for this year to at least 20%.
The clinical side of the business was less stellar. Sanofi-Aventis announced that it was dropping two compounds that were in phase 2-b testing (pranalcasan for arthritis and osanetant for schizophrenia). The company also announced mixed data from a phase 3 depression trial (the European study showed decent efficacy, but the North American study did not), and it's quite possible that another phase 3 study may be required before approval.
On a more positive note, the company had better success in trials studying insomnia, smoking cessation, and cancer. Investors should also remember that Sanofi-Aventis is awaiting Food and Drug Administration approval for Acomplia for obesity and smoking; Exubera, which is inhaled insulin, with Pfizer
These late-stage drugs (as well as the 35 compounds in phases 2b or 3 testing) will be important. Sanofi-Aventis faces the threat of losing patent protection for Lovenox and Plavix, and should that happen, it would need these new drugs to maintain growth.
I won't make the case that Sanofi-Aventis is dirt-cheap or significantly undervalued. Stocks like Merck
For more healthy pharmaceutical Takes:
- Vioxx Brings the Pain
- Glaxo Keeps It Going
- Bristol-Myers' Road to Better Health
- Waiting for Sanofi's Next Act
Pfizer is a Motley Fool Inside Value selection; Merck is an Income Investor pick. For more investment ideas, tryany of our newsletters.
More from The Motley Fool
IBM Struggled With the Tax Man in the 4th Quarter
A long-awaited return to actual sales growth was overshadowed by a $5.5 billion one-time tax charge.
1 Big Improvement That Apple Needs to Bring to the New iPhone SE
It's time for a new display.
Sears Holdings' Store Closures: No Problem for Seritage Growth Properties
Seritage Growth Properties gets most of its rent from Sears and Kmart. But the numerous store closures at both chains won't hurt Seritage as it works to increase its rental income and diversify its tenant base.